First Time Loading...

Creo Medical Group PLC
LSE:CREO

Watchlist Manager
Creo Medical Group PLC Logo
Creo Medical Group PLC
LSE:CREO
Watchlist
Price: 36.5 GBX Market Closed
Updated: May 22, 2024

Net Margin
Creo Medical Group PLC

-85.9%
Current
-26 333%
Average
2%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-85.9%
=
Net Income
-25.1m
/
Revenue
29.2m

Net Margin Across Competitors

Country Company Market Cap Net
Margin
UK
Creo Medical Group PLC
LSE:CREO
128.1m GBP
-86%
US
Abbott Laboratories
NYSE:ABT
179.1B USD
14%
US
Intuitive Surgical Inc
NASDAQ:ISRG
142B USD
27%
US
Stryker Corp
NYSE:SYK
125.7B USD
16%
IE
Medtronic PLC
NYSE:MDT
113.2B USD
13%
US
Boston Scientific Corp
NYSE:BSX
111.5B USD
12%
US
Becton Dickinson and Co
NYSE:BDX
68.2B USD
7%
DE
Siemens Healthineers AG
XETRA:SHL
59.8B EUR
8%
US
Edwards Lifesciences Corp
NYSE:EW
54.2B USD
23%
US
Dexcom Inc
NASDAQ:DXCM
51.9B USD
17%
CN
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
369.4B CNY
34%
Creo Medical Group PLC
LSE:CREO
Country UK
Market Cap 128.1m GBP
Net Margin
-86%
Abbott Laboratories
NYSE:ABT
Country US
Market Cap 179.1B USD
Net Margin
14%
Intuitive Surgical Inc
NASDAQ:ISRG
Country US
Market Cap 142B USD
Net Margin
27%
Stryker Corp
NYSE:SYK
Country US
Market Cap 125.7B USD
Net Margin
16%
Medtronic PLC
NYSE:MDT
Country IE
Market Cap 113.2B USD
Net Margin
13%
Boston Scientific Corp
NYSE:BSX
Country US
Market Cap 111.5B USD
Net Margin
12%
Becton Dickinson and Co
NYSE:BDX
Country US
Market Cap 68.2B USD
Net Margin
7%
Siemens Healthineers AG
XETRA:SHL
Country DE
Market Cap 59.8B EUR
Net Margin
8%
Edwards Lifesciences Corp
NYSE:EW
Country US
Market Cap 54.2B USD
Net Margin
23%
Dexcom Inc
NASDAQ:DXCM
Country US
Market Cap 51.9B USD
Net Margin
17%
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
Country CN
Market Cap 369.4B CNY
Net Margin
34%

Profitability Report

View the profitability report to see the full profitability analysis for Creo Medical Group PLC.

Full Profitability Report

See Also

Summary
CREO intrinsic value, competitors valuation, and company profile.
DCF Valuation
CREO stock valuation using Discount Cash Flow valuation method.
Relative Valuation
CREO stock valuation using valuation multiples.
Wall Street Estimates
CREO price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
CREO stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-85.9%
=
Net Income
-25.1m
/
Revenue
29.2m
What is the Net Margin of Creo Medical Group PLC?

Based on Creo Medical Group PLC's most recent financial statements, the company has Net Margin of -85.9%.

ALPHA SPREAD
Join more than 139,400+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.